HRA Pharma is a specialty pharmaceutical company, which focuses on the management of severe adrenal diseases and Cushing’s syndrome. We are committed to improve the management of such disorders, which are greatly underserved.
It has been our dream from the outset to improve the lives of patients by providing treatments for these otherwise unmet medical needs and spreading awareness of these diseases. We dare to do this through collaborative partnerships, focused research and pivotal clinical trials; our goal is to develop and share the most adapted treatments possible.
At HRA Pharma, we listen to your needs and act accordingly.
Specific treatments for rare diseases in endocrinology
Our research and partnerships are far reaching, as we strive to continuously push the boundaries of treatments in endocrinology.
In France, for example, we have research agreements with the Institut Gustave Roussy , for the evaluation of the impact of mitotane concentration in lipoproteins on tumor response in the treatment of advanced adrenocortical carcinoma.
In Italy, we have a cooperation agreement with the Universitá di Torino - the sponsor of the ADIUVO trial ‘Efficacy of adjuvant mitotane treatment in prolonging recurrence-free survival in patients with adrenocortical carcinoma at low-intermediate risk of recurrence’, which is an ongoing international study.
We also work in close collaboration with the European Network for the Study of Adrenal Tumors (ENS@T). Having supported several projects including the set-up of a registry for adrenocortical carcinoma (ACC) and a number of clinical trials.
HRA Pharma was also instrumental - in conjunction with ENS@T - in launching the ACC awards. The idea is that every year, two awards (one for preclinical and one for clinical research) are given for innovative work accomplished in the field of adrenocortical cancer.
Through such initiatives our dream to help patients in endocrinology / rare diseases is realized, as we dare to innovate and collaborate, to ultimately share our know-how and much-needed adapted treatments.
Providing key therapies in the management of Cushing’s syndrome and adrenal tumors
Cushing’s syndrome - a rare hormonal disorder caused by prolonged exposure of the body’s tissues to high levels of the hormone cortisol – is another area of expertise that has been developed by HRA Pharma – for the benefit of patients worldwide, who suffer from this rare and severe illness.
Various symptoms characterize Cushing’s syndrome and surgery remains treatment of choice whenever possible. However, we are actively investigating pharmacologic options with a focus on ensuring that products are accessible to patients around the world. Management of Cushing’s syndrome should be individualised and doctors will offer effective treatment strategy for each patient, on a case by case basis.
Today, our endocrinology portfolio includes three essential treatments:
- Metopirone® (metyrapone, 250 mg, Soft capsules)
- Lysodren® (mitotane, 500mg, Tablets)
- Ketoconazole HRATM (ketoconazole, 200mg, Tablets)
Always at your service to provide treatment and support
In 2005, HRA Pharma set up LYSOSAFE® Service, a completely free service** associated with the use of our medicine Lysodren® (mitotane, 500 mg tablets).
The service is available to all European hospitals using this treatment.
LYSOSAFE® Service is a completely free service**, which includes shipping samples to a unique centralized bioanalytical center, testing the samples following standard protocols by a GC/MS assay (gas chromatography-mass spectrometry) and returning the results within a few days.
For further information, or to obtain medical Information, please don’t hesitate to contact us.
** Free of charge transport in Europe only